ArticleFrontiers in immunology2026
Gegen Qinlian decoction alleviates ulcerative colitis by remodeling the gut microbiota-bile acid axis and inhibiting NLRP3-mediated pyroptosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gegen Qinlian Decoction (GQD) is used to treat intestinal disorders, but its mechanism in ulcerative colitis (UC) induced by combined high-fat diet (HFD) and dextran sulfate sodium (DSS) exposure remains unclear. Methods: A UC mouse model was induced by HFD plus DSS. GQD constituents were identified by UPLC-MS/MS. Colonic pathology and barrier integrity were assessed by H&E and immunofluorescence. Gut microbiota and bile acids were analyzed by 16S rRNA gene sequencing and targeted metabolomics. Transcriptomics, ELISA, Western blotting, fecal microbiota transplantation (FMT), and molecular docking were used to investigate mechanisms. LPS-stimulated Caco-2 cells were treated with 20 or 50 μM DCA; cell viability, NLRP3 inflammasome-related gene expression, and ZO-1/Occludin immunofluorescence were evaluated. Results: GQD ameliorated gut dysbiosis, decreasing the Firmicutes/Bacteroidetes ratio, increasing Conclusion: GQD alleviates UC induced by combined HFD and DSS exposure by reshaping the gut microbiota and correcting bile acid dysregulation, thereby inhibiting NLRP3 inflammasome activation. This study highlights the gut microbiota-bile acid axis in GQD's therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.